AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02929693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
Study NCT04459546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education, training booklet, 3 months tele health
Description: Patient education includes general disease information, COPD self-management and symptom control. The education face-to-face and practical training was provided by the researcher. The training booklet was prepared by the researcher. The readability of the booklet was very easy and its comprehensibility was tested by pre-application. Tele monitoring was done by the researcher for support and motivation. The participants were called 4 times by phone.
Study NCT01834521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based screening and tailored support
Study NCT01816477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ON-Q soaker catheter system
Description: ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly.
Study NCT01816477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural (ropivicaine 0.25%)
Description: Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
Study NCT00752791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
Study NCT00535106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated external defibrillator (Philips FR2+ AED)
Description: Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
Study NCT00535106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartCPR
Description: Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
Study NCT00535106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed defibrillation
Description: In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
Study NCT05498246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic partial nephrectomy
Description: Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter
Study NCT01146132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Conventional diet +/- wine
Description: usual eating habits
Study NCT01163643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Vehicle
Description: Placebo Comparator: Vehicle BID for 12 weeks.
Study NCT01163643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% BOL-303242-X ophthalmic suspension
Description: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Study NCT01163643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% BOL-303242-X ophthalmic suspension AM
Description: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
Study NCT01163643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% BOL-303242-X ophthalmic suspension PM
Description: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
Study NCT01253525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1121B )
Description: 8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
Study NCT01253525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
Study NCT01007864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piribedil
Description: Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
Study NCT01007864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole or ropinirole
Description: continuation of pre-study treatment regimen
Study NCT00463827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT00463827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 40mg
Study NCT00463827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: Matched placebo
Study NCT03674554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: titanium bases using intra oral luting cement technique
Description: a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
Study NCT03674554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transmucosal abutment
Description: a full-arch screw-retained implant prosthesis with transmucosal abutment
Study NCT00847405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate
Description: 100 mg Tablets
Study NCT00847405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex®
Description: 100 mg Tablet
Study NCT00959101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide and metformin combination tablet
Description: Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
Study NCT00959101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide and metformin combination tablet
Description: Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
Study NCT00959101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
Study NCT00959101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
Study NCT02278133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WNT974
Study NCT00962143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Achilles repair with OrthADAPT augmentation
Description: Achilles repair with OrthADAPT augmentation
Study NCT00962143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles repair without OrthADAPT Augmentation
Description: Achilles repair without OrthADAPT Augmentation
Study NCT04323033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEPTUN C stent
Description: Neptun C is balloon-expanding cobalt-chromium stent.
Study NCT03766165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
Study NCT03766165 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants will receive job announcements only.
Study NCT02233296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 2 discrete doses separated by 6 days.
Study NCT03377504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
Study NCT02278133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study NCT04834700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: online group
Description: In terms of teaching ultrasound, video lectures will be conducted rather than hands-on, which is the traditional method.
Study NCT02497898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells (CIK)
Description: Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
Study NCT04839263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FAST TRACK protocol
Description: Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op
Study NCT01976065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
Study NCT01976065 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment
Description: Standard Treatment no use of study drug
Study NCT03377504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy and exercise program
Description: Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
Study NCT00147901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCCam
Description: After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
Study NCT02000739 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetically Informed Therapy
Description: If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
Study NCT02965222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the time-lapse videography
Description: The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
Study NCT01584180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid infusions, 0.9%NaCl or Ringer's
Description: Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
Study NCT01584180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMCOOLS Brain.Pad
Description: Passive external neck cooling with 1 EMCOOLS Brain.Pad
Study NCT04465279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trifocal diffractive intraocular lens
Description: Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
Study NCT04202926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real coil
Description: active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
Study NCT04202926 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham coil
Description: sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
Study NCT00926510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language toolkit
Description: Simple toolkit of interactive things to stimulate language.
Study NCT00926510 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safety counseling
Description: Smoke detector and general safety counseling
Study NCT04396002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Life Space Questionnaire
Description: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
Study NCT04396002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low Luminance Questionnaire
Description: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.
Study NCT04396002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast sensitivity under dim illumination
Description: Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.
Study NCT04396002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field under dim illumination (MAIA)
Description: Sensitivity in the central visual area will be assessed under dim illumination
Study NCT04396002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Macular Pigment Optical Density (MPOD)
Description: Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.
Study NCT04396002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dark Adaptation
Description: After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
Study NCT03784690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized intraoperative BP management
Description: In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status.
Study NCT03784690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard intraoperative BP management
Description: Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
Study NCT05381298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Margin Elevation using resin composite
Description: After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.
Study NCT05381298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Crown Lengthening
Description: Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
Study NCT01667913 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: 6 minutes walking test
Study NCT02020122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: duloxetine 60mg
Study NCT02020122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pregabalin 150mg
Study NCT02020122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: non active placebo
Study NCT02020122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non active placebo
Study NCT02713711 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
Study NCT02713711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
Study NCT02713711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balneophototherapy
Description: Twelve sessions of both balneotherapy and phototherapy treatments.
Study NCT00540787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation, antiarrhythmic drugs
Description: Patients receive either treatment.
Study NCT00540787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
Description: Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
Study NCT00540787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoCool Radiofrequency Catheter
Description: Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
Study NCT03943589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: All subjects will receive imlifidase (Day 1) prior to standard care IVIg
Study NCT03364348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study NCT03364348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT03364348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ado-Trastuzumab Emtansine
Description: Given IV